Noble Life Sciences, a full service, GLP (Good Laboratory Practice)-compliant and non-GLP preclinical contract research organization (CRO), today announced that its Board of Directors has appointed Srujana Cherukuri as Chief Executive Officer (CEO) effective immediately. The board also announced that Dr. Cherukuri is now majority owner of Noble Life Sciences.
“With the acquisition of Spring Valley Laboratories, Noble Life Sciences has grown from a contract research organization offering in vivo drug services in small animals to a full service CRO offering services for the development of drugs, devices, and vaccines in a range of large and small animals,” said Ken Carter, Chairman of the Board. “Because the integration of Spring Valley Laboratories is complete, now is the right time to appoint a CEO who will continue Noble’s growth. Dr. Cherukuri was key to the successful integration process, we are enthusiastic about her vision to ensure Noble’s continued growth and future success.”